Syndax Pharmaceuticals

Syndax is a late stage oncology company whose lead product candidate is entinostat, an oral, selective histone deacetylase inhibitor (HDACi) that is being developed to treat therapy-resistant cancers through an epigenetic mechanism. Entinostat was recently granted Breakthrough Therapy designation by the FDA based on data from the company’s completed Phase 2b clinical trial for ER+ metastatic breast cancer.

Syndax Pharmaceuticals

Waltham, MA

Website

NASDAQ

SNDX

07.06.2016
Syndax Expands Pipeline With Exclusive Worldwide License Agreemen…

Read More

03.02.2016
Syndax Announces Pricing of Initial Public Offering

Read More